PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
 
J Clin Invest. 1986 June; 77(6): 1909–1916.
PMCID: PMC370551

Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator.

Abstract

Vascular endothelium possesses multiple procoagulant properties, including synthesis and expression of Factor V. We studied the effects of homocysteine on the regulation of endothelial cell Factor V activity. Elevated levels of homocysteine are associated with the congenital thrombotic disorder homocystinuria. Treatment of cultured endothelial cells with 0.5-10 mM homocysteine had no effect on cell morphology, but did increase Factor V activity and prothrombin activation by Factor Xa. A radioimmunoassay for endothelial cell Factor V demonstrated that homocysteine treatment did not increase Factor V antigen levels. 125I-prothrombin was activated by treated endothelial cells and Factor Xa in the presence of thrombin inhibitors. Exogenous 125I-Factor V was cleaved by homocysteine-treated but not control endothelial cells. 125I-Factor V cleavage products distinct from those generated by thrombin and Factor Xa were identified. These data provide evidence for regulation of endothelial cell Factor V activity, and indicate that increased Factor V activity associated with homocysteine-treated vascular endothelium results primarily from induction of an activator of Factor V.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Rosenberg RD, Rosenberg JS. Natural anticoagulant mechanisms. J Clin Invest. 1984 Jul;74(1):1–6. [PMC free article] [PubMed]
  • Rodgers GM, Greenberg CS, Shuman MA. Characterization of the effects of cultured vascular cells on the activation of blood coagulation. Blood. 1983 Jun;61(6):1155–1162. [PubMed]
  • Wight TN. Vessel proteoglycans and thrombogenesis. Prog Hemost Thromb. 1980;5:1–39. [PubMed]
  • Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A. 1981 Apr;78(4):2249–2252. [PubMed]
  • Weksler BB, Marcus AJ, Jaffe EA. Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci U S A. 1977 Sep;74(9):3922–3926. [PubMed]
  • Loskutoff DJ, Edgington TE. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci U S A. 1977 Sep;74(9):3903–3907. [PubMed]
  • Maynard JR, Dreyer BE, Stemerman MB, Pitlick FA. Tissue-factor coagulant activity of cultured human endothelial and smooth muscle cells and fibroblasts. Blood. 1977 Sep;50(3):387–396. [PubMed]
  • Wiggins RC, Loskutoff DJ, Cochrane CG, Griffin JH, Edgington TS. Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells. J Clin Invest. 1980 Jan;65(1):197–206. [PMC free article] [PubMed]
  • Stern DM, Drillings M, Nossel HL, Hurlet-Jensen A, LaGamma KS, Owen J. Binding of factors IX and IXa to cultured vascular endothelial cells. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4119–4123. [PubMed]
  • Stern DM, Nawroth PP, Kisiel W, Handley D, Drillings M, Bartos J. A coagulation pathway on bovine aortic segments leading to generation of Factor Xa and thrombin. J Clin Invest. 1984 Dec;74(6):1910–1921. [PMC free article] [PubMed]
  • Rodgers GM, Shuman MA. Characterization of the interaction between factor Xa and bovine aortic endothelial cells. Biochim Biophys Acta. 1985 Mar 21;844(3):320–329. [PubMed]
  • Rodgers GM, Shuman MA. Prothrombin is activated on vascular endothelial cells by factor Xa and calcium. Proc Natl Acad Sci U S A. 1983 Nov;80(22):7001–7005. [PubMed]
  • Cerveny TJ, Fass DN, Mann KG. Synthesis of coagulation factor V by cultured aortic endothelium. Blood. 1984 Jun;63(6):1467–1474. [PubMed]
  • RAPAPORT SI, SCHIFFMAN S, PATCH MJ, AMES SB. The importance of activation of antihemophilic globulin and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity. Blood. 1963 Feb;21:221–236. [PubMed]
  • Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med. 1974 Sep 12;291(11):537–543. [PubMed]
  • Uhlemann ER, TenPas JH, Lucky AW, Schulman JD, Mudd SH, Shulman NR. Platelet survival and morphology in homocystinuria due to cystathionine synthase deficiency. N Engl J Med. 1976 Dec 2;295(23):1283–1286. [PubMed]
  • Hill-Zobel RL, Pyeritz RE, Scheffel U, Malpica O, Engin S, Camargo EE, Abbott M, Guilarte TR, Hill J, McIntyre PA, et al. Kinetics and distribution of 111Indium-labeled platelets in patients with homocystinuria. N Engl J Med. 1982 Sep 23;307(13):781–786. [PubMed]
  • Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res. 1980 Apr 1;18(1-2):113–121. [PubMed]
  • Ratnoff OD. Activation of Hageman factor by L-homocystine. Science. 1968 Nov 29;162(3857):1007–1009. [PubMed]
  • Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973 Nov;52(11):2745–2756. [PMC free article] [PubMed]
  • Miletich JP, Broze GJ, Jr, Majerus PW. The synthesis of sulfated dextran beads for isolation of human plasma coagulation factors II, IX, and X. Anal Biochem. 1980 Jul 1;105(2):304–310. [PubMed]
  • Kane WH, Majerus PW. Purification and characterization of human coagulation factor V. J Biol Chem. 1981 Jan 25;256(2):1002–1007. [PubMed]
  • Canfield WM, Kisiel W. Evidence of normal functional levels of activated protein C inhibitor in combined Factor V/VIII deficiency disease. J Clin Invest. 1982 Dec;70(6):1260–1272. [PMC free article] [PubMed]
  • Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. [PubMed]
  • LEWIS ML, WARE AG. A one-stage method for the determination of accelerator globulin. Proc Soc Exp Biol Med. 1953 Dec;84(3):640–643. [PubMed]
  • BACHMANN F, DUCKERT F, KOLLER F. The Stuart-Prower factor assay and its clinical significance. Thromb Diath Haemorrh. 1958 May 1;2(1-2):24–38. [PubMed]
  • Tracy PB, Peterson JM, Nesheim ME, McDuffie FC, Mann KG. Interaction of coagulation factor V and factor Va with platelets. J Biol Chem. 1979 Oct 25;254(20):10354–10361. [PubMed]
  • Isaacs JD, Savion N, Gospodarowicz D, Fenton JW, 2nd, Shuman MA. Covalent binding of thrombin to specific sites on corneal endothelial cells. Biochemistry. 1981 Jan 20;20(2):398–403. [PubMed]
  • Foster WB, Nesheim ME, Mann KG. The factor Xa-catalyzed activation of factor V. J Biol Chem. 1983 Nov 25;258(22):13970–13977. [PubMed]
  • Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA., Jr Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984 Aug 1;160(2):618–623. [PMC free article] [PubMed]
  • Kisiel W, Canfield WM, Ericsson LH, Davie EW. Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry. 1977 Dec 27;16(26):5824–5831. [PubMed]
  • Comp PC, Esmon CT. Activated protein C inhibits platelet prothrombin-converting activity. Blood. 1979 Dec;54(6):1272–1281. [PubMed]
  • Kettner C, Shaw E. Inactivation of trypsin-like enzymes with peptides of arginine chloromethyl ketone. Methods Enzymol. 1981;80(Pt 100):826–842. [PubMed]
  • de Groot PG, Willems C, Boers GH, Gonsalves MD, van Aken WG, van Mourik JA. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest. 1983 Oct;13(5):405–410. [PubMed]
  • Kane WH, Mruk JS, Majerus PW. Activation of coagulation factor V by a platelet protease. J Clin Invest. 1982 Nov;70(5):1092–1100. [PMC free article] [PubMed]
  • Tracy PB, Nesheim ME, Mann KG. Proteolytic alterations of factor Va bound to platelets. J Biol Chem. 1983 Jan 10;258(1):662–669. [PubMed]
  • Dudman NP, Wilcken DE. Homocysteine thiolactone and experimental homocysteinemia. Biochem Med. 1982 Apr;27(2):244–253. [PubMed]
  • Sinha AK, Dutta-Roy AK, Chiu HC, Stewart GJ, Colman RW. Coagulant factor Xa inhibits prostacyclin formation in human endothelial cells. Role of factor V. Arteriosclerosis. 1985 May-Jun;5(3):244–249. [PubMed]
  • Stern DM, Nawroth PP, Harris K, Esmon CT. Cultured bovine aortic endothelial cells promote activated protein C-protein S-mediated inactivation of factor Va. J Biol Chem. 1986 Jan 15;261(2):713–718. [PubMed]
  • Nesheim ME, Taswell JB, Mann KG. The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J Biol Chem. 1979 Nov 10;254(21):10952–10962. [PubMed]
  • Kane WH, Majerus PW. The interaction of human coagulation factor Va with platelets. J Biol Chem. 1982 Apr 10;257(7):3963–3969. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation